Table 1.

Summary of therapeutic approaches modulating NETosis in arterial and venous thrombo-embolic diseases.

NET-inhibiting agent	Mechanism of action		Author
Cl-amidine	PAD4 inhibitor	Carotid artery plaque, murine	Knight et al. (105)
GSK484	PAD4 inhibitor	Acute myocardial infarction, murine	Du et al. (106)
DNAse I	NET degradation	Photothrombotic stroke model, murine	Peña-Martínez et al. (107)
DNAse I	NET degradation	Atherosclerosis model, murine	Warnatsch et al. (65)
DNAse I	NET degradation	Acute myocardial infarction, human	Mangold et al. (87)
DNase I + rhADAMTS13	NET degradation	Myocardial ischemia/reperfusion (MI/R) injury, murine	Savchenko et al. (108)
DNAse I	NET degradation	Acute ischemic stroke, human	Ducroux et al. (89)
DNAse I	NET degradation	DVT, mice	von Brühl et al. (46)
DNAse I	NET degradation	DVT, mice	Brill et al. (109)
ASA	COX inhibitor	Acute lung injury, murine	Ortiz-Muñoz et al. (110)
ASA	COX inhibitor	Sepsis model, murine	Carestia et al. (111)
Clopidogrel	P2Y12 inhibitor	Acute lung injury, murine	Pulavendran et al. (112)
Clopidogrel	P2Y12 inhibitor	Renal ischemia reperfusion injury, murine	Jansen et al. (113)
Ticagrelor	P2Y12 inhibitor	Pneumonia, human	Sexton et al.(114)
Ticagrelor	P2Y12 inhibitor	Acute myocardial infarction, human	Mitsios et al. (115)